Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03647137 · ClinicalTrials.gov registry record

Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD

A clinical trial, sponsored by VA Office of Research and Development.

Completed
Registry status
53
Enrollment target

NCT03647137: Completed study, sponsored by VA Office of Research and Development.

NCT03647137 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03647137 has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
53 participants
Enrollment target

Study Summary

Early stage Parkinson disease (PD) is characterized by a 'honeymoon' phase in terms of responsiveness of motor symptoms, including gait, to dopaminergic pharmacotherapy. Advancing PD is associated with disabling axial motor complications, such as freezing of gait (FoG), with decreased or even refractory dopamine responsiveness in over 50% of patients. The management of dopamine resistant gait problems represents the most important unmet need in PD. This study will related detailed motor testing to brain PET imaging to see if certain molecules (or lack thereof) involved with neurologic transmission in the brain are involved with FoG.

Primary Outcome

Participants are considered as L-DOPA insensitive if their freezing of gait is not observed to be any different between motor assessment while on dopaminergic medication and off dopaminergic medication.

Interventions

  • OTHER Detailed motor testing, including FoG, in PD subjects

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2016-06-07
Est. Completion 2021-05-26
VA Office of Research and Development

1,668 total trials

What the finished NCT03647137 record still lists

NCT03647137 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Detailed motor testing, including FoG, in PD subjects is the first listed.

NCT03647137 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03647137 about?

NCT03647137 is a clinical study titled "Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD". Early stage Parkinson disease (PD) is characterized by a 'honeymoon' phase in terms of responsiveness of motor symptoms, including gait, to dopaminergic pharmacotherapy. Advancing PD is associated with disabling axial motor complications, such as freezing of gait (FoG), with decreased or even refrac...

What is the current status of trial NCT03647137?

This trial is currently completed. The enrollment target is 53 participants. The study started on 2016-06-07. Estimated completion is 2021-05-26.

What interventions are being tested in trial NCT03647137?

The interventions under investigation include: Detailed motor testing, including FoG, in PD subjects (OTHER).

Who is sponsoring clinical trial NCT03647137?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04177004 · 53 participants · Phase 1

    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

  • NCT04199741 · 53 participants · Phase 1

    PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

  • NCT04835129 · 53 participants · Phase 2

    Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

  • NCT04913805 · 53 participants · Phase 2

    Matching Perfusion and Metabolic Activity in HFpEF

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03647137, the US trial registry maintained by the National Library of Medicine. NCT03647137 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.